^
No biomarker
Penile Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
capecitabine
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cetuximab
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
5-fluorouracil + mitomycin
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
carboplatin + paclitaxel
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cisplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
cisplatin + 5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
imiquimod
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Penile Cancer
TIP
Sensitive: A2 - Guideline
MSI-H/dMMR
Penile Cancer
pembrolizumab
Sensitive: A2 - Guideline
TMB-H
Penile Cancer
pembrolizumab
Sensitive: C1 - Off-label
PD-L1 expression
Penile Cancer
pembrolizumab
Sensitive: C1 - Off-label
TMB-H + PD-L1 expression + MSI-L/dMMR
Penile Cancer
nivolumab + ipilimumab
Sensitive: C4 – Case Studies
TMB-H + PD-L1 expression
Penile Cancer
toripalimab
Sensitive: C4 – Case Studies
CDKN2A mutation
Penile Cancer
nivolumab
Sensitive: C4 – Case Studies